The hypothesis for the TAME trial is that aging processes continue and can be intervened upon even after the onset of the first disease.

“so it seems to me that the biggest challenge here is not the funding it's not the study design it's the conceptual leap it's it's a completely different paradigm of how we think about delaying death”

“and I'm not going to get to the FDA with the indication for aging”

“our hypothesis is that the the aging part of your biology doesn't stop working when you had your first disease it's still going to get your next disease okay and if we think biologically like that we should be able to intervene as we do with animals quite late also”